DK1534320T3 - Apolipoprotein L-I til behandling af trypanosomen sygdomme - Google Patents

Apolipoprotein L-I til behandling af trypanosomen sygdomme

Info

Publication number
DK1534320T3
DK1534320T3 DK03766078T DK03766078T DK1534320T3 DK 1534320 T3 DK1534320 T3 DK 1534320T3 DK 03766078 T DK03766078 T DK 03766078T DK 03766078 T DK03766078 T DK 03766078T DK 1534320 T3 DK1534320 T3 DK 1534320T3
Authority
DK
Denmark
Prior art keywords
apolipoprotein
treatment
diseases
derivated
polypeptide
Prior art date
Application number
DK03766078T
Other languages
Danish (da)
English (en)
Inventor
Etienne Pays
Luc Vanhamme
Philippe Poelvoorde
Francoise Paturiaux-Hanocq
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Application granted granted Critical
Publication of DK1534320T3 publication Critical patent/DK1534320T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/101Bovine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DK03766078T 2002-08-02 2003-08-04 Apolipoprotein L-I til behandling af trypanosomen sygdomme DK1534320T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE200200465 2002-08-02
BE200200649 2002-11-14
PCT/BE2003/000131 WO2004012757A2 (en) 2002-08-02 2003-08-04 Apolipoprotein l-i for the treatment or diagnosis of prypanosomaldiseases

Publications (1)

Publication Number Publication Date
DK1534320T3 true DK1534320T3 (da) 2007-04-02

Family

ID=31496437

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03766078T DK1534320T3 (da) 2002-08-02 2003-08-04 Apolipoprotein L-I til behandling af trypanosomen sygdomme

Country Status (9)

Country Link
US (1) US7585511B2 (de)
EP (1) EP1534320B1 (de)
AT (1) ATE345808T1 (de)
AU (1) AU2003254426A1 (de)
DE (1) DE60309888T2 (de)
DK (1) DK1534320T3 (de)
ES (1) ES2278201T3 (de)
PT (1) PT1534320E (de)
WO (1) WO2004012757A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039645A1 (en) * 2005-10-06 2007-04-12 Vib Vzw African trypanosomiasis therapy with a nanobody-conjugated human trypanolytic factor
WO2008063603A2 (en) 2006-11-20 2008-05-29 President And Fellows Of Harvard College Methods, compositions, and kits for treating pain and pruritis
WO2009124941A2 (en) * 2008-04-07 2009-10-15 Aarhus Universitet Trypanocidal compounds targeted to trypanosomes interior
WO2010129267A2 (en) 2009-04-27 2010-11-11 University Of Georgia Research Foundation, Inc. Anti-trypanosomal peptides and uses thereof
CA2767646C (en) 2009-07-10 2019-01-29 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
US20110030078A1 (en) * 2009-07-31 2011-02-03 New York University Trypanosome resistant non-human transgenic animal
WO2011020497A1 (en) * 2009-08-18 2011-02-24 Universite Libre De Bruxelles C-terminal mutant of apolipoprotein l-i and its therapeutical or prophylactic use
WO2011020865A1 (en) * 2009-08-18 2011-02-24 Universite Libre De Bruxelles Apolipoprotein l- i variants and their use
US9023355B2 (en) * 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
US9828637B2 (en) * 2010-04-18 2017-11-28 Wake Forest University Health Sciences Methods of predicting predisposition to or risk of kidney disease
USRE49076E1 (en) 2010-04-18 2022-05-17 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
US20130251740A1 (en) * 2010-10-26 2013-09-26 Rockefeller University (The) Immunogenic agents
WO2012095508A1 (en) * 2011-01-13 2012-07-19 Universite Libre De Bruxelles Apol3 for use in the treatment of trypanosoma infectious diseases
EP2489365A1 (de) * 2011-02-17 2012-08-22 Université Libre de Bruxelles Wildtyp-Apolipoprotein l-i zur Prävention von Nierenerkrankungen
EP2688584A4 (de) * 2011-03-25 2015-05-20 Univ Columbia Pegylierte menschliche hdl-partikel und verfahren zu ihrer herstellung
US20150291683A1 (en) * 2012-11-16 2015-10-15 Merck Sharp & Dohme Corp. Modified apol1 polypeptides
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US20150307591A1 (en) * 2012-12-21 2015-10-29 Merck Sharp & Dohme Corp. On-column refolding and purifying of lipoproteins
WO2014137674A1 (en) * 2013-03-08 2014-09-12 Regeneron Pharmaceuticals, Inc. Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
CN107105632A (zh) 2014-11-10 2017-08-29 豪夫迈·罗氏有限公司 肾病动物模型及其治疗剂
KR20180069782A (ko) 2015-08-03 2018-06-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 하전 이온 채널 블록커 및 이용 방법
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2022527438A (ja) 2019-03-11 2022-06-02 ノシオン セラピューティクス,インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
EP3937945A4 (de) 2019-03-11 2023-01-04 Nocion Therapeutics, Inc. Geladene ionenkanalblocker und verfahren zur verwendung
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2022527731A (ja) 2019-03-11 2022-06-06 ノシオン セラピューティクス,インコーポレイテッド エステル置換イオンチャンネル遮断薬および使用方法
JP7513713B2 (ja) 2019-11-06 2024-07-09 ノシオン セラピューティクス,インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
BR112022008575A2 (pt) 2019-11-06 2022-08-09 Nocion Therapeutics Inc Bloqueadores de canal iônico carregado e métodos para uso
CN115279731A (zh) 2020-03-11 2022-11-01 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
DK1049767T3 (da) * 1998-01-08 2005-09-19 Aventis Pharma Inc En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)

Also Published As

Publication number Publication date
PT1534320E (pt) 2007-02-28
US20060263348A1 (en) 2006-11-23
ES2278201T3 (es) 2007-08-01
DE60309888T2 (de) 2007-06-21
EP1534320A2 (de) 2005-06-01
ATE345808T1 (de) 2006-12-15
AU2003254426A1 (en) 2004-02-23
WO2004012757A2 (en) 2004-02-12
WO2004012757A3 (en) 2004-04-15
EP1534320B1 (de) 2006-11-22
DE60309888D1 (de) 2007-01-04
AU2003254426A8 (en) 2004-02-23
US7585511B2 (en) 2009-09-08

Similar Documents

Publication Publication Date Title
DK1534320T3 (da) Apolipoprotein L-I til behandling af trypanosomen sygdomme
DE602007009095D1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
DK1049767T3 (da) En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A)
DE602006013778D1 (de) Zusammensetzung enthaltend vorgeformte Persäure und einen Bleichmittelkatalysator
BRPI0512944A (pt) agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1
DE69901840D1 (de) Neue salzform von pantoprazol
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE410235T1 (de) Behandlung von ballastwasser
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE50213015D1 (de) Lipase-varianten
ATE315400T1 (de) Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
ATE458750T1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
ATE541566T1 (de) Zusammensetzungen zur behandlung von erkrankungen der augenoberfläche
ATE533842T1 (de) Bromelainbestandteil
BRPI0510031A (pt) domìnios semelhantes a egf de mucina3
ATE354361T1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
DK1276495T3 (da) Anvendelse af rekombinante lungesurfactant-præparater til tidlig behandling af akutte lungesygdomme
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
DK1601352T3 (da) Kombineret anvendelse af et fibrat og orlistat til behandling af fedme
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
ATE321545T1 (de) Calcium-lactat und molkenpermeat zur senkung des triglyceridspiegels
ATE450293T1 (de) Verwendung von molkenpermeat zur behandlung des metabolischen syndroms
ATE382054T1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
ATE250417T1 (de) Verwendung von 2-amino-4-(4-fluoronaphth-1-yl)-6- isopropylpyrimidine zur behandlung von erkrankungen des magen-darm-traktes